Targeted controls in clinical immunohistochemistry: A useful approach to quality assurance

American Journal of Clinical Pathology

Volumn 117, Issue 1, 2002, Pages 7-8

  Wick, Mark R ^a   Swanson, Paul E ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; TRASTUZUMAB;

BREAST CARCINOMA; CANCER CELL CULTURE; CELL TRANSFORMATION; CLINICAL LABORATORY; DRUG SENSITIVITY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; MEDICAL PRACTICE; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS;

HUMANS; IMMUNOHISTOCHEMISTRY; LABORATORY TECHNIQUES AND PROCEDURES; QUALITY CONTROL; REFERENCE STANDARDS;

EID: 0036141313     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/7LQJ-LQQ0-JHYH-Y8U2     Document Type: Editorial

References (10)

1. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer
2. Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridization
3. HER-2: A discussion of testing approaches in the USA
4. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer
5. Current use of HER-2 tests
6. Biological rationale for HER-2/neu (c-erbB-2) as a target for monoclonal therapy
7. Mechanism of action of anti-HER-2 monoclonal antibodies
8. Pharmacology and therapeutic use of trastuzumab in breast cancer
9. Labels, disclaimers, and rules (oh, my!): Analyte-specific reagents and practice of immunohistochemistry
10. Consensual interpretative guidelines for diagnostic immunohistochemistry